The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.
Many types of human cancer are characterized by deregulation of the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors. In some cancers, genomic events causing overactivity of individual HER family members are etiologically linked with the pathogenesis of these cancers, and constitute the driving signaling function underlying their tumorigenic behavior. HER3 stands out among this family as the only member lacking catalytic kinase function. Cancers with driving HER3 amplifications or mutations have not been found, and studies of its expression in tumors have been only weakly provocative. However, substantial evidence, predominantly from experimental models, now suggest that its non-catalytic functions are critically important in many cancers driven by its' HER family partners. Furthermore, new insights into the mechanism of activation in the HER family has provided clear evidence of functionality in the HER3 kinase domain. The convergence of structural, mechanistic, and experimental evidence highlighting HER3 functions that may be critical in tumorigenesis have now led to renewed efforts towards identification of cancers or subtypes of cancers wherein HER3 function may be important in tumor progression or drug resistance. It appears now that its failure to earn the traditional definition of an oncogene has allowed the tumor promoting functions of HER3 to elude the effects of cancer therapeutics. But experimental science has now unmasked the unpretentious role of HER3 in cancer biology, and the next generation of cancer therapies will undoubtedly perform much better because of it.
Amin
Dhara N
DN
University of California, San Francisco, Medicine, San Francisco, CA 94143-1387, USA.
Campbell
Marcia R
MR
Moasser
Mark M
MM
D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D020893:Receptor, ErbB-3 / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
D020893:Receptor, ErbB-3
J Biol Chem. 2000 Mar 24;275(12):8641-9
10722704
J Clin Oncol. 2006 Sep 10;24(26):4317-23
16896008
Ai Zheng. 2004 May;23(5):568-72
15142456
J Cancer Res Clin Oncol. 2000 Apr;126(4):205-11
10782893
Mol Cell Biol. 1994 Jun;14(6):3550-8
7515147
BMC Cancer. 2006 Feb 28;6:46
16507107
Int J Cancer. 2006 Jan 15;118(2):284-9
16049961
Science. 2007 May 18;316(5827):1039-43
17463250
J Clin Invest. 2006 Oct;116(10):2695-706
16906227
Ann Oncol. 2008 Jun;19(6):1068-74
18283035
Cancer Res. 2005 Sep 1;65(17):7591-5
16140923
Clin Mol Pathol. 1996 Aug;49(4):M199-202
16696074
Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22
19143635
Lung Cancer. 2008 Nov;62(2):193-201
18450321
Ann Oncol. 2009 Jun;20(6):1026-31
19179558
Mol Syst Biol. 2005;1:2005.0008
16729043
Cancer Cell. 2010 Mar 16;17(3):298-310
20227043
Crit Rev Oncol Hematol. 2010 May;74(2):73-8
19481955
Int J Cancer. 1995 Jun 22;64(3):202-6
7622309
J Biol Chem. 1996 Feb 16;271(7):3884-90
8632008
Pigment Cell Melanoma Res. 2009 Dec;22(6):773-84
19659570
Cancer Cell. 2010 Jan 19;17(1):98-110
20129251
Sci Transl Med. 2010 Jan 27;2(16):16ra7
20371474
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
17440164
Biochem J. 1997 Mar 15;322 ( Pt 3):757-63
9148746
Clin Cancer Res. 2002 Dec;8(12):3933-42
12473609
Mol Cancer Ther. 2003 Oct;2(10):971-84
14578462
EMBO J. 1996 May 15;15(10):2452-67
8665853
Int J Cancer. 2003 Sep 20;106(5):758-65
12866037
Nature. 2006 Jan 12;439(7073):168-74
16273093
Melanoma Res. 2004 Jun;14(3):207-10
15179190
Lancet Oncol. 2009 Jun;10(6):581-8
19394894
Cancer Res. 2008 Jul 15;68(14):5878-87
18632642
Cell. 2006 Jun 16;125(6):1137-49
16777603
J Neuropathol Exp Neurol. 2006 Aug;65(8):769-75
16896310
J Biol Chem. 2005 Mar 4;280(9):8238-47
15611073
FEBS Lett. 2004 Jul 2;569(1-3):332-6
15225657
Nat Genet. 2009 Oct;41(10):1127-32
19718025
Br J Cancer. 1996 Jul;74(2):229-33
8688326
Clin Cancer Res. 2009 Jun 15;15(12):4147-56
19509167
Mol Cell Biol. 2007 Mar;27(6):2180-8
17210635
J Clin Invest. 2009 Sep;119(9):2702-13
19690388
Cancer Res. 2005 Dec 15;65(24):11478-85
16357156
Adv Cancer Res. 2005;94:29-86
16095999
Cancer Res. 2007 Feb 15;67(4):1645-52
17308105
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6
8058768
Int J Cancer. 2008 Jul 15;123(2):340-347
18398842
Mol Cell Biol. 1994 Jan;14(1):492-500
8264617
Dev Cell. 2007 Apr;12(4):487-502
17419990
Mod Pathol. 1997 Feb;10(2):142-8
9127320
Clin Cancer Res. 2000 Nov;6(11):4217-25
11106235
J Biol Chem. 2006 Jul 14;281(28):19310-9
16690615
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7792-6
1715580
J Pathol. 1993 Jul;170(3):271-8
8133400
Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21608-13
20007378
Oncogene. 2008 Jun 19;27(27):3870-4
18264138
Mol Cell Biol. 1996 Oct;16(10):5276-87
8816440
Clin Cancer Res. 2005 Mar 15;11(6):2163-8
15788662
Clin Cancer Res. 2009 Aug 1;15(15):4829-37
19622585
J Clin Oncol. 2002 Feb 1;20(3):719-26
11821453
J Pathol. 2003 Jul;200(3):290-7
12845624
J Neuropathol Exp Neurol. 2007 Aug;66(8):740-9
17882018
Science. 2004 Jun 4;304(5676):1497-500
15118125
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8
12853564
Cancer Res. 2006 Dec 1;66(23):11279-86
17145873
Breast Cancer Res. 2008;10(1):R2
18182100
J Biol Chem. 2004 Nov 5;279(45):47050-6
15345710
Br J Cancer. 1998 Nov;78(10):1385-90
9823984
Chin Med Sci J. 1997 Jun;12(2):67-70
11324501
Int J Biochem Cell Biol. 2007;39(5):851-6
17254832
Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83
10482197
Clin Cancer Res. 2009 May 15;15(10):3315-24
19447869
Nature. 2007 Jan 25;445(7126):437-41
17206155
Cancer Res. 2008 Oct 15;68(20):8286-94
18922900
Cancer Cell. 2010 Jan 19;17(1):77-88
20129249
Cancer Res. 2009 Mar 15;69(6):2195-200
19276373
Hum Pathol. 1998 Aug;29(8):771-7
9712416
PLoS Med. 2005 Mar;2(3):e73
15737014
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Clin Cancer Res. 2004 Oct 15;10(20):6779-88
15501954
Oncogene. 1989 Oct;4(10):1175-83
2571965
EMBO J. 1994 Jun 15;13(12):2831-41
8026468
Int J Cancer. 2006 Dec 15;119(12):2986-7
16998794
Glia. 2005 Aug 15;51(3):217-28
15812817
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93
15731348
Br J Cancer. 1995 Apr;71(4):758-62
7710941
J Clin Oncol. 1999 Sep;17(9):2639-48
10561337
Clin Cancer Res. 2008 Aug 15;14(16):5188-97
18698037
Int J Cancer. 2009 Dec 1;125(11):2565-75
19530240